HTIG

BIOLOGICAL4 trials

Sponsors

Zhuhai Trinomab Pharmaceutical Co., Ltd., Genrix (Shanghai) Biopharmaceutical Co., Ltd., Sinovac Life Sciences Co., Ltd.

Conditions

Tetanus

Phase 1

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

CompletedNCT06302374

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Tetanus

Start: 2023-03-04End: 2024-02-19Updated: 2024-03-08

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants

CompletedNCT06939777

Sinovac Life Sciences Co., Ltd.Tetanus

Start: 2025-04-28End: 2026-03-30Updated: 2026-06-03

Phase 2

Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

CompletedNCT05625477

Zhuhai Trinomab Pharmaceutical Co., Ltd.Tetanus

Start: 2022-04-18End: 2022-10-18Updated: 2025-09-16

Phase 3

A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

RecruitingNCT06635798

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Tetanus

Start: 2024-09-03End: 2025-03-04Target: 582Updated: 2024-10-10